Clinical trial of levocarnitine combined with alprostadil in the treatment of diabetic nephropathy
10.13699/j.cnki.1001-6821.2016.13.006
- VernacularTitle:左卡尼汀联合前列地尔治疗糖尿病肾病的临床研究
- Author:
Zhao-Xia XIA
1
;
Wei LU
;
Dai-Jie WANG
;
Dian-Mei XI
;
Xue-Mei ZHANG
Author Information
1. 泸州市人民医院 内分泌科
- Keywords:
levocarnitine;
alprostadil;
diabetic nephropathy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(13):1172-1174
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safty of le-vocarnitine combined with alprostadil in the treatment of diabetic ne-phropathy.Methods A total of 68 patients with diabetic nephropathy were randomly divided into control group ( n=34 ) and treatment group (n=34).Control group was given alprostadil 1 mL, qd by intravenous drip.Treatment group was received levocarnitine 1 g, qd by intravenous drip on the basis of control group .The course of two groups was 28 d. The clinical efficacy , biochemical indexes before and after treatment and the incidence of adverse drug reactions were compared between two groups.Results After treatment , the total effective rate of control group was significantly lower than that of treatment group ( 67.65% vs 94.12%, P<0.05).After treatment, the levels of serum 24 h urinary protein , urinary microglobulin , urea nitrogen , cystatin C , homocysteine , glycosylated hemoglobin , transforming growth factor -β1 ,Ⅳcollagen in two groups were significantly decreased ( P<0.05 ) , and those indexes of treatment group after treatment were significantly lower than those of control group (P<0.05).After treatment, the levels of serum of serum creatinine , 25 -hydroxy vitamin D 3 in two groups were decreased with significant difference ( P <0.05 ) , and the treatment group was more obvious ( P<0.05 ).The incidence of adverse drug reactions in control group was significantly higher than that in treat -ment group (23.53%vs 8.82%,P<0.05 ) .Conclusion Levocarnitine combined with alprostadil have a definitive clinical efficacy and safety for the treatment of diabetic nephropathy .
